Now let me produce the final consolidated review.

## Summary
2-3 sentence summary of the paper's contribution.

## Strengths
- strength 1 with evidence
- strength 2 with evidence

## Weaknesses
### Fatal
### Major
### Minor
### Trivial

## Nice-to-Haves

## Removed Points

## Novel Insights

## Suggestions

## Score and Decision

---

Here is my final review:

## Summary

This paper applies Mask R-CNN to detect and segment four Plasmodium species (P. falciparum, P. malariae, P. ovale, P. vivax) from 971 microscopic images of clinical blood smears collected in Rwanda. The model achieves mAP of 0.9575 and 0.9459 on two species, and the paper claims pixel-level segmentation improves over prior bounding-box and single-species approaches. The contribution is primarily a application-oriented study: deploying a standard instance-segmentation architecture (Mask R-CNN) on a new multi-species malaria dataset.

## Strengths

- **Real-world clinical dataset**: The 971 images come from actual clinical samples collected through Rwanda's healthcare quality-control system (Rwanda Biomedical Centre), include both thick and thin film smears (Section 4.1), and follow ethical protocols for routine healthcare data (Section 4.1, line 54). This provides more ecologically valid evaluation than synthetic or lab-only datasets used in some prior work.

- **Multi-species scope**: The paper addresses four Plasmodium species in a single framework, which is a clinically relevant advance over prior work that focused predominantly on P. falciparum alone (Section 2, lines 21-25).

## Weaknesses

### Fatal

None.

### Major

- **No quantitative comparison with any baseline method under controlled conditions.** The paper repeatedly claims superiority over prior methods — Faster R-CNN (Bogale et al., 2024), YOLOv5 (Karasira et al., 2024), and U-Net (Akpo et al., 2024) — but provides zero numerical comparisons on the same dataset with the same evaluation protocol. Section 5.2 states "Unlike YOLOv5, which struggled to recognize P. falciparum due to a small dataset, our model performs well across all species" (line 101), but no YOLOv5 or Faster R-CNN or U-Net is actually re-trained or evaluated on this paper's dataset. Without a controlled experiment, these superiority claims are unsubstantiated. This is the paper's most critical weakness.

- **Missing results for the mixed-infection experiment.** Section 4.2 states that experiments were conducted "on all of them combined to test for mixed infections" (line 61), yet no results for this experiment are presented anywhere in the paper. Neither the text nor Table 1 (which is an embedded image) provide mAP values for the combined four-species scenario, nor is there any analysis of performance on mixed-infection images.

- **No segmentation-specific evaluation metrics.** The paper's core claimed advantage over prior work is pixel-level instance segmentation (Mask R-CNN's mask predictions vs. coarse bounding boxes). Yet the only quantitative metric reported is mAP, which is a detection metric. No mask-specific metrics are provided: no mask IoU, no Dice coefficient, no pixel-level precision/recall, no boundary F1-score. Without such metrics, the claim that "high-quality masks that precisely delineate the shape and boundaries" (Section 3, paragraph 3) provides a concrete advantage cannot be evaluated.

- **Core mAP values for P. falciparum and P. ovale are not reported in the text.** The abstract and Section 5.2 only report mAP for P. vivax (0.9575) and P. malariae (0.9459). The corresponding values for P. falciparum and P. ovale — two of the four species central to the paper's multi-species claim — are not mentioned in the running text. Table 1 is an embedded image that may contain these numbers, but the text gives the reader no way to assess the worst-performing species, which is critical for evaluating the method's practical usefulness.

- **Overclaimed contributions relative to evidence.** The paper characterizes its results as "a breakthrough in automated diagnosis" (Section 5.2, line 90) and "a significant step forward in microscopy-based diagnosis" (Section 7, line 122). The actual contribution is applying a standard 2017 architecture (Mask R-CNN) to a moderately-sized dataset with no novel architectural modifications, no ablation studies, and no baseline comparisons. These claims significantly exceed what the experiments demonstrate.

### Minor

- **No error bars or statistical significance.** All results appear to come from a single training run per experiment. For a top-tier venue, reporting variance across multiple runs (or at minimum discussing the limitation) is expected.

- **Dataset distribution imbalance not addressed.** P. vivax has only 175 images compared to 278 for P. falciparum, and the 70/20/10 split leaves roughly 17-18 test images for the smallest class. The paper does not discuss whether this affects reliability of per-species mAP estimates.

- **No ablation studies.** There is no analysis of design choices (e.g., effect of different backbones, impact of the mask branch vs. detection-only, effect of image size 256×256 vs. larger resolutions, or the stated decision to forgo data augmentation). Such ablations would significantly strengthen the empirical contribution.

### Trivial

- Section 4.2 states training used a batch size of 8 "as we classified images into three or more classes" — the connection between batch size and number of classes is unclear and should be clarified.

## Nice-to-Haves

- Releasing the annotated dataset and model weights would significantly enhance reproducibility and community impact.
- Adding real-world clinical validation (flagged by the authors themselves in Section 6) would strengthen practical relevance.

## Removed Points

None — the Harsh Critic input was empty/incomplete ("I"), so no points needed removal. The above weaknesses are based on direct reading of the paper.

## Novel Insights

None beyond the paper's own contributions.

## Suggestions

1. **Add quantitative baseline comparisons**: Retrain Faster R-CNN, YOLOv5, and U-Net on this paper's dataset under the same protocol and report mAP, mask IoU, and inference speed. This is the single most important action to substantiate the paper's central claims.

2. **Report segmentation-specific metrics**: At minimum, add mask IoU and Dice coefficient for evaluation, to support the claimed advantage of pixel-level segmentation over bounding boxes.

3. **Report all per-species and mixed-infection results** explicitly in the text, with confidence intervals or standard deviations across multiple runs.

4. **Tone down overclaims**: Replace "breakthrough" and "significant step forward" with measured language appropriate to an application paper with no novel methodology.

## Score and Decision

The paper applies a standard architecture to a new domain and dataset, which can be a useful contribution, but it falls short of ICLR's bar due to: (i) absence of any quantitative baseline comparisons — the core claim of "outperforming prior methods" is unsupported; (ii) missing results for a stated experiment (mixed infections); (iii) lack of segmentation-specific metrics for a segmentation method; and (iv) overclaimed contributions. These issues are addressable in principle but substantially weaken the paper as submitted.

MY FINAL SCORE: <score>3.5</score>
MY FINAL DECISION: <decision>Reject</decision>